Biological and clinical heterogeneity of MYCN-amplified medulloblastoma

Andrey Korshunov, Marc Remke, Marcel Kool, Thomas Hielscher, Paul A. Northcott, Dan Williamson, Elke Pfaff, Hendrik Witt, David T.W. Jones, Marina Ryzhova, Yoon-Jae Cho, Andrea Wittmann, Axel Benner, William A. Weiss, Andreas Von Deimling, Wolfram Scheurlen, Andreas E. Kulozik, Steven C. Clifford, V. Peter Collins, Frank Westermann & 3 others Michael D. Taylor, Peter Lichter, Stefan M. Pfister

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Focal high-level amplifications of MYC (or MYCC) define a subset of high-risk medulloblastoma patients. However, the prognostic role of MYCN oncogene amplification remains unresolved. We aimed to evaluate the prognostic value of this alteration alone and in combination with biological modifiers in 67 pediatric medulloblastomas with MYCN amplification (MYCN-MB). Twenty-one MYCN-MB were examined using gene expression profiling and array-CGH, whereas for 46 tumors immunohistochemical analysis and FISH were performed. All 67 tumors were further subjected to mutational analyses. We compared molecular, clinical, and prognostic characteristics both within biological MYCN-MB groups and with non-amplified tumors. Transcriptomic analysis revealed SHH-driven tumorigenesis in a subset of MYCN MBs indicating a biological dichotomy of MYCN-MB. Activation of SHH was accompanied by variant-specific cytogenetic aberrations including deletion of 9q in SHH tumors. Non-SHH MB were associated with gain of 7q and isochromosome 17q/17q gain. Among clinically relevant variables, SHH subtype and 10q loss for non-SHH tumors comprised the most powerful markers of favorable prognosis in MYCN-MB. In conclusion, we demonstrate considerable heterogeneity within MYCN-MB in terms of genetics, tumor biology, and clinical outcome. Thus, assessment of disease group and 10q copy-number status may improve risk stratification of this group and may delineate MYCN-MB with the same dismal prognosis as MYC amplified tumors. Furthermore, based on the enrichment of MYCN and GLI2 amplifications in SHH-driven medulloblastoma, amplification of these downstream signaling intermediates should be taken into account before a patient is enrolled into a clinical trial using a smoothened inhibitor.

Original languageEnglish (US)
Pages (from-to)515-527
Number of pages13
JournalActa Neuropathologica
Volume123
Issue number4
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Medulloblastoma
Neoplasms
Isochromosomes
Gene Expression Profiling
Oncogenes
Chromosome Aberrations
Carcinogenesis
Clinical Trials
Pediatrics

Keywords

  • 10q loss
  • Medulloblastoma
  • MYCN
  • SHH pathway

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Korshunov, A., Remke, M., Kool, M., Hielscher, T., Northcott, P. A., Williamson, D., ... Pfister, S. M. (2012). Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathologica, 123(4), 515-527. https://doi.org/10.1007/s00401-011-0918-8

Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. / Korshunov, Andrey; Remke, Marc; Kool, Marcel; Hielscher, Thomas; Northcott, Paul A.; Williamson, Dan; Pfaff, Elke; Witt, Hendrik; Jones, David T.W.; Ryzhova, Marina; Cho, Yoon-Jae; Wittmann, Andrea; Benner, Axel; Weiss, William A.; Von Deimling, Andreas; Scheurlen, Wolfram; Kulozik, Andreas E.; Clifford, Steven C.; Collins, V. Peter; Westermann, Frank; Taylor, Michael D.; Lichter, Peter; Pfister, Stefan M.

In: Acta Neuropathologica, Vol. 123, No. 4, 01.04.2012, p. 515-527.

Research output: Contribution to journalArticle

Korshunov, A, Remke, M, Kool, M, Hielscher, T, Northcott, PA, Williamson, D, Pfaff, E, Witt, H, Jones, DTW, Ryzhova, M, Cho, Y-J, Wittmann, A, Benner, A, Weiss, WA, Von Deimling, A, Scheurlen, W, Kulozik, AE, Clifford, SC, Collins, VP, Westermann, F, Taylor, MD, Lichter, P & Pfister, SM 2012, 'Biological and clinical heterogeneity of MYCN-amplified medulloblastoma', Acta Neuropathologica, vol. 123, no. 4, pp. 515-527. https://doi.org/10.1007/s00401-011-0918-8
Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D et al. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathologica. 2012 Apr 1;123(4):515-527. https://doi.org/10.1007/s00401-011-0918-8
Korshunov, Andrey ; Remke, Marc ; Kool, Marcel ; Hielscher, Thomas ; Northcott, Paul A. ; Williamson, Dan ; Pfaff, Elke ; Witt, Hendrik ; Jones, David T.W. ; Ryzhova, Marina ; Cho, Yoon-Jae ; Wittmann, Andrea ; Benner, Axel ; Weiss, William A. ; Von Deimling, Andreas ; Scheurlen, Wolfram ; Kulozik, Andreas E. ; Clifford, Steven C. ; Collins, V. Peter ; Westermann, Frank ; Taylor, Michael D. ; Lichter, Peter ; Pfister, Stefan M. / Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. In: Acta Neuropathologica. 2012 ; Vol. 123, No. 4. pp. 515-527.
@article{678974c474874b24aae09424e92e74e6,
title = "Biological and clinical heterogeneity of MYCN-amplified medulloblastoma",
abstract = "Focal high-level amplifications of MYC (or MYCC) define a subset of high-risk medulloblastoma patients. However, the prognostic role of MYCN oncogene amplification remains unresolved. We aimed to evaluate the prognostic value of this alteration alone and in combination with biological modifiers in 67 pediatric medulloblastomas with MYCN amplification (MYCN-MB). Twenty-one MYCN-MB were examined using gene expression profiling and array-CGH, whereas for 46 tumors immunohistochemical analysis and FISH were performed. All 67 tumors were further subjected to mutational analyses. We compared molecular, clinical, and prognostic characteristics both within biological MYCN-MB groups and with non-amplified tumors. Transcriptomic analysis revealed SHH-driven tumorigenesis in a subset of MYCN MBs indicating a biological dichotomy of MYCN-MB. Activation of SHH was accompanied by variant-specific cytogenetic aberrations including deletion of 9q in SHH tumors. Non-SHH MB were associated with gain of 7q and isochromosome 17q/17q gain. Among clinically relevant variables, SHH subtype and 10q loss for non-SHH tumors comprised the most powerful markers of favorable prognosis in MYCN-MB. In conclusion, we demonstrate considerable heterogeneity within MYCN-MB in terms of genetics, tumor biology, and clinical outcome. Thus, assessment of disease group and 10q copy-number status may improve risk stratification of this group and may delineate MYCN-MB with the same dismal prognosis as MYC amplified tumors. Furthermore, based on the enrichment of MYCN and GLI2 amplifications in SHH-driven medulloblastoma, amplification of these downstream signaling intermediates should be taken into account before a patient is enrolled into a clinical trial using a smoothened inhibitor.",
keywords = "10q loss, Medulloblastoma, MYCN, SHH pathway",
author = "Andrey Korshunov and Marc Remke and Marcel Kool and Thomas Hielscher and Northcott, {Paul A.} and Dan Williamson and Elke Pfaff and Hendrik Witt and Jones, {David T.W.} and Marina Ryzhova and Yoon-Jae Cho and Andrea Wittmann and Axel Benner and Weiss, {William A.} and {Von Deimling}, Andreas and Wolfram Scheurlen and Kulozik, {Andreas E.} and Clifford, {Steven C.} and Collins, {V. Peter} and Frank Westermann and Taylor, {Michael D.} and Peter Lichter and Pfister, {Stefan M.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1007/s00401-011-0918-8",
language = "English (US)",
volume = "123",
pages = "515--527",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Biological and clinical heterogeneity of MYCN-amplified medulloblastoma

AU - Korshunov, Andrey

AU - Remke, Marc

AU - Kool, Marcel

AU - Hielscher, Thomas

AU - Northcott, Paul A.

AU - Williamson, Dan

AU - Pfaff, Elke

AU - Witt, Hendrik

AU - Jones, David T.W.

AU - Ryzhova, Marina

AU - Cho, Yoon-Jae

AU - Wittmann, Andrea

AU - Benner, Axel

AU - Weiss, William A.

AU - Von Deimling, Andreas

AU - Scheurlen, Wolfram

AU - Kulozik, Andreas E.

AU - Clifford, Steven C.

AU - Collins, V. Peter

AU - Westermann, Frank

AU - Taylor, Michael D.

AU - Lichter, Peter

AU - Pfister, Stefan M.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Focal high-level amplifications of MYC (or MYCC) define a subset of high-risk medulloblastoma patients. However, the prognostic role of MYCN oncogene amplification remains unresolved. We aimed to evaluate the prognostic value of this alteration alone and in combination with biological modifiers in 67 pediatric medulloblastomas with MYCN amplification (MYCN-MB). Twenty-one MYCN-MB were examined using gene expression profiling and array-CGH, whereas for 46 tumors immunohistochemical analysis and FISH were performed. All 67 tumors were further subjected to mutational analyses. We compared molecular, clinical, and prognostic characteristics both within biological MYCN-MB groups and with non-amplified tumors. Transcriptomic analysis revealed SHH-driven tumorigenesis in a subset of MYCN MBs indicating a biological dichotomy of MYCN-MB. Activation of SHH was accompanied by variant-specific cytogenetic aberrations including deletion of 9q in SHH tumors. Non-SHH MB were associated with gain of 7q and isochromosome 17q/17q gain. Among clinically relevant variables, SHH subtype and 10q loss for non-SHH tumors comprised the most powerful markers of favorable prognosis in MYCN-MB. In conclusion, we demonstrate considerable heterogeneity within MYCN-MB in terms of genetics, tumor biology, and clinical outcome. Thus, assessment of disease group and 10q copy-number status may improve risk stratification of this group and may delineate MYCN-MB with the same dismal prognosis as MYC amplified tumors. Furthermore, based on the enrichment of MYCN and GLI2 amplifications in SHH-driven medulloblastoma, amplification of these downstream signaling intermediates should be taken into account before a patient is enrolled into a clinical trial using a smoothened inhibitor.

AB - Focal high-level amplifications of MYC (or MYCC) define a subset of high-risk medulloblastoma patients. However, the prognostic role of MYCN oncogene amplification remains unresolved. We aimed to evaluate the prognostic value of this alteration alone and in combination with biological modifiers in 67 pediatric medulloblastomas with MYCN amplification (MYCN-MB). Twenty-one MYCN-MB were examined using gene expression profiling and array-CGH, whereas for 46 tumors immunohistochemical analysis and FISH were performed. All 67 tumors were further subjected to mutational analyses. We compared molecular, clinical, and prognostic characteristics both within biological MYCN-MB groups and with non-amplified tumors. Transcriptomic analysis revealed SHH-driven tumorigenesis in a subset of MYCN MBs indicating a biological dichotomy of MYCN-MB. Activation of SHH was accompanied by variant-specific cytogenetic aberrations including deletion of 9q in SHH tumors. Non-SHH MB were associated with gain of 7q and isochromosome 17q/17q gain. Among clinically relevant variables, SHH subtype and 10q loss for non-SHH tumors comprised the most powerful markers of favorable prognosis in MYCN-MB. In conclusion, we demonstrate considerable heterogeneity within MYCN-MB in terms of genetics, tumor biology, and clinical outcome. Thus, assessment of disease group and 10q copy-number status may improve risk stratification of this group and may delineate MYCN-MB with the same dismal prognosis as MYC amplified tumors. Furthermore, based on the enrichment of MYCN and GLI2 amplifications in SHH-driven medulloblastoma, amplification of these downstream signaling intermediates should be taken into account before a patient is enrolled into a clinical trial using a smoothened inhibitor.

KW - 10q loss

KW - Medulloblastoma

KW - MYCN

KW - SHH pathway

UR - http://www.scopus.com/inward/record.url?scp=84862278147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862278147&partnerID=8YFLogxK

U2 - 10.1007/s00401-011-0918-8

DO - 10.1007/s00401-011-0918-8

M3 - Article

VL - 123

SP - 515

EP - 527

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 4

ER -